CABA Cabaletta Bio Inc.

FDA Catalyst Company
1.34
-0.08  -6%
Previous Close 1.42
Open 1.5
52 Week Low 1.17
52 Week High 14.9499
Market Cap $38,829,353
Shares 28,977,129
Float 27,512,197
Enterprise Value $-68,065,477
Volume 29,283
Av. Daily Volume 173,627
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Mizuho Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/18/2022
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/18/2022
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 12/15/2021
Wells Fargo Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 12/08/2021
Mizuho Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 06/30/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/17/2021
Chardan Capital Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/08/2021
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 10/13/2020
Morgan Stanley Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/15/2020

Latest News

  1. PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational data through 6 months of follow-up in cohorts A1 through A3, safety data through 3 months and persistence data through 1 month of follow-up in cohorts A1 through A4 from the DesCAARTes™ trial at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting being held in Washington, D.C. from May 16-19, 2022.

    "At ASGCT, we presented updated interim data showing that DSG3-CAART has had a favorable safety profile with no dose limiting toxicities or cytokine…

    View Full Article
  2. PHILADELPHIA, May 17, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 11:00 a.m. ET in Miami, FL.

    A live webcast of the presentation will be available on the News and Events section of the Company's website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days.

    About Cabaletta Bio
    Cabaletta Bio (NASDAQ:CABA) is a clinical-stage biotechnology…

    View Full Article
  3. DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming scientific meetings in mid-2022 –

    Multiple abstracts accepted for presentation at upcoming ASGCT and SID Annual Meetings

    – MuSK-CAART first-in-human trial on track to commence in 2022 following Fast Track Designation and IND clearance from the FDA –

    PHILADELPHIA, May 12, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today reported financial results for the first quarter ended March 31, 2022, and provided a business update.

    "The…

    View Full Article
  4. PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that data from its two lead programs, DSG3-CAART and MuSK-CAART, will be presented at multiple upcoming scientific meetings in May 2022. The DSG3-CAART presentations will include Phase 1 clinical data from the ongoing DesCAARTes™ trial. The MuSK-CAART presentations will contain preclinical safety and activity studies to support potential clinical development of precision engineered T-cell therapy for MuSK-associated myasthenia gravis.

    Desmoglein 3 chimeric autoantibody receptor T (DSG3-CAART) cells…

    View Full Article
  5. PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Gwendolyn Binder, Ph.D., President of Science and Technology, will present a pre-recorded company presentation at the 21st Annual Needham Virtual Healthcare Conference, which will become available for on-demand viewing on Tuesday, April 12, 2022 at 3:45 p.m. ET.

    The pre-recorded presentation will be available on the News and Events section of the Company's website at www.cabalettabio.com. Replays of the presentation will be available on the website for 30 days.

    About Cabaletta Bio
    Cabaletta Bio…

    View Full Article
View All Cabaletta Bio Inc. News